FibroGen Announces Positive Phase 3 Pooled Roxadustat Safety and Efficacy Results for Treatment of Anemia in Chronic Kidney Disease

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/13/2026

1. ADBE
2. SPCX
3. USO
4. SPY
5. RH
6. NVDA
7. RKLB
8. MSFT
9. CRM
10. CRWV

Go back to FibroGen Announces Positive Phase 3 Pooled Roxadustat Safety and Efficacy Results for Treatment of Anemia in Chronic Kidney Disease
(NASDAQ: FGEN) Delayed: 9.71 --0 (-0%)
Previous Close $9.71    52 Week High $31.90 
Open $9.71    52 Week Low $14.38 
Day High $9.71    P/E N/A 
Day Low $9.71    EPS $0.00 
Volume 745,000